DiscoverFDA Drug Safety PodcastsFDA withdrew its approval for the cancer medicine Ukoniq (umbralisib) due to safety concerns
FDA withdrew its approval for the cancer medicine Ukoniq (umbralisib) due to safety concerns

FDA withdrew its approval for the cancer medicine Ukoniq (umbralisib) due to safety concerns

Update: 2022-07-07
Share

Description

Listen to an audio podcast of the 6/1/22 for Ukoniq . FDA withdrew its approval for the cancer medicine Ukoniq (active ingredient umbralisib) due to safety concerns. Ukoniq was approved to treat two specific types of lymphoma: marginal zone lymphoma (MZL) and follicular lymphoma (FL)
Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

FDA withdrew its approval for the cancer medicine Ukoniq (umbralisib) due to safety concerns

FDA withdrew its approval for the cancer medicine Ukoniq (umbralisib) due to safety concerns

U.S. Food and Drug Administration, Center for Drug Evaluation and Research